Abstract:Abstract Background Although immune checkpoint inhibitor (ICI) is regarded as a breakthrough in cancer therapy, only a limited fraction of patients benefit from it. Cancer stemness can be the potential culprit in ICI resistance, but direct clinical evidence is lacking. Methods Publicly available scRNA-Seq datasets derived from ICI-treated patients were collected and analyzed to elucidate the association between cancer stemness and ICI response. A novel stemness signature (Stem.Sig) was developed and validated using large-scale pan-cancer data, including 34 scRNA-Seq datasets, The Cancer Genome Atlas (TCGA) pan-cancer cohort, and 10 ICI transcriptomic cohorts. The therapeutic value of Stem.Sig genes was further explored using 17 CRISPR datasets that screened potential immunotherapy targets. Results Cancer stemness, as evaluated by CytoTRACE, was found to be significantly associated with ICI resistance in melanoma and basal cell carcinoma (both P < 0.001). Significantly negative association was found between Stem.Sig and anti-tumor immunity, while positive correlations were detected between Stem.Sig and intra-tumoral heterogenicity (ITH) / total mutational burden (TMB). Based on this signature, machine learning model predicted ICI response with an AUC of 0.71 in both validation and testing set. Remarkably, compared with previous well-established signatures, Stem.Sig achieved better predictive performance across multiple cancers. Moreover, we generated a gene list ranked by the average effect of each gene to enhance tumor immune response after genetic knockout across different CRISPR datasets. Then we matched Stem.Sig to this gene list and found Stem.Sig significantly enriched 3% top-ranked genes from the list ( P = 0.03), including EMC3, BECN1, VPS35, PCBP2, VPS29, PSMF1, GCLC, KXD1, SPRR1B, PTMA, YBX1, CYP27B1, NACA, PPP1CA, TCEB2, PIGC, NR0B2, PEX13, SERF2, and ZBTB43, which were potential therapeutic targets. Conclusions We revealed a robust link between cancer stemness and immunotherapy resistance and developed a promising signature, Stem.Sig, which showed increased performance in comparison to other signatures regarding ICI response prediction. This signature could serve as a competitive tool for patient selection of immunotherapy. Meanwhile, our study potentially paves the way for overcoming immune resistance by targeting stemness-associated genes.

Synthetic viability induces resistance to immune checkpoint inhibitors in cancer cells

A Landscape of Synthetic Viable Interactions in Cancer

Synthetic Enforcement of STING Signaling in Cancer Cells Appropriates the Immune Microenvironment for Checkpoint Inhibitor Therapy.

The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma

Synthetic biology approaches for improving the specificity and efficacy of cancer immunotherapy

Eliminating a barrier: Aiming at VISTA, reversing MDSC-mediated T cell suppression in the tumor microenvironment

Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors

Ratio of the Interferon-Γ Signature to the Immunosuppression Signature Predicts Anti-Pd-1 Therapy Response in Melanoma

The biological essence of synthetic lethality: Bringing new opportunities for cancer therapy

Mi-2β Promotes Immune Evasion in Melanoma by Activating EZH2 Methylation

Chemotherapy induces immune checkpoint VISTA expression in tumor cells via HIF-2alpha

Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment

Integrated analysis of single-cell and bulk RNA sequencing data reveals a pan-cancer stemness signature predicting immunotherapy response

Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors

Systematic evaluation of the predictive gene expression signatures of immune checkpoint inhibitors in metastatic melanoma

Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment

Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response

Mi-2β-targeted inhibition induces immunotherapy response in melanoma

A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade

Senescence drives immunotherapy resistance by inducing an immunosuppressive tumor microenvironment

Immune Checkpoint Inhibitors in Cancer Therapy—How to Overcome Drug Resistance?